Nucleic Acid Aptamers Is Fastest Growing Segment Fueling The Growth Of The Global Aptamers Market
![]() |
Aptamers Market |
The global Aptamers Market is
estimated to be valued at US$ 6265.49 Mn
in 2023 and is expected to exhibit a CAGR
of 18.4% over the forecast period 2023 to 2030, as highlighted in a new
report published by Coherent Market Insights.
Market Overview:
Aptamers are short,
single-stranded DNA or RNA molecules that are selected through an in vitro
selection process called Systematic Evolution of Ligands by Exponential
enrichment (SELEX) to bind targeted molecules with high affinity and
specificity. Aptamers have advantages over conventional antibodies such as low
immunogenicity, longer shelf life, smaller size, and ease of production.
Aptamers have applications in diagnostics, therapeutics, and research.
Market key trends:
Nucleic acid aptamers is the
fastest growing segment fueling the growth of the global aptamers market.
Nucleic acid aptamers have advantages over protein-based aptamers such as lower
molecular weight, better stability at different pH and temperature, easier
production, and lesser batch-to-batch variation. Nucleic acid aptamers have
applications in disease diagnosis, drug delivery, and targeted cancer therapy.
Increasing R&D investment by leading players for development of novel
nucleic acid aptamers is propelling the growth of this segment. For instance,
in October 2022, Vivonics Inc. received funding of US$ 14 Mn to advance
development of its lead nucleic acid aptamer candidates for oncology indications.
Segment Analysis
The global aptamers market can be
segmented based on type, application, technology, and end-user. Based on type,
the diagnostics segment is expected to dominate the market during the forecast
period. This is due to the increasing use of aptamers in lateral flow assays,
electrochemical biosensors, and flow cytometry for disease diagnosis. The
segment is exhibiting high demand for early and accurate disease diagnosis.
Key Takeaways
The Global
Aptamers Market Size is expected to witness high growth, exhibiting a
CAGR of 18.4% over the forecast period, due to increasing R&D investments
in aptamer-based therapeutics and diagnostics.
Regional analysis - North America is expected to be the fastest
growing as well as dominating regional market during the forecast period. This
is attributed to the growing biotechnology and pharmaceutical industries and
rising funding for drug discovery and development research activities in the
region.
Key players - Key players operating in the aptamers market are
Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS,
Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies,
Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca,
GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc.,
SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc. Novartis AG and
Aptamer Sciences Inc. are identified as the industry leaders due to their
robust product portfolios and global market presence.
Get More Insights Here
https://www.newsstatix.com/aptamers-market-share-size-forecast-outlook-2023-2030/
Comments
Post a Comment